Cathie Wood's $362 Million CRISPR Bet: Hidden Catalyst
Cathie Wood’s big bet on CRISPR Therapeutics signals more than faith in gene editing. This article digs into the unde...
Index movements reflect changes in component stock prices, earnings, macro data, and capital flows. This overview highlights the main drivers behind daily swings.
18,176 articlesCathie Wood’s big bet on CRISPR Therapeutics signals more than faith in gene editing. This article digs into the unde...
Craving steady, lasting cash flow from your investments? Discover how a two-stock, buy-and-hold approach using Coca‑C...
The Trade Desk prepares to report quarterly results as investors grapple with a steep stock drop, focusing on revenue...
Owlet's Q4 2025 results reveal a company balancing growth with a path toward profitability. This article disentangles...
HeartBeam heads into 2025 earnings with a mix of potential breakthroughs and headwinds. This guide explains what the ...
VR Adviser recently disclosed a substantial sale of Ocular Therapeutix shares, triggering questions about what it mea...
If you’ve got $5,000 to invest, these three AI-driven stock picks offer a balanced blend of growth potential and prac...
As Turning Point Brands rode a wave of rising oral nicotine sales, one fund made a bold move: trimming a multi-millio...
Credo Technology posted robust Q3 results and announced sizable TAM expansions, but investors are weighing margin pre...
AMZY, the YieldMax AMZN Option Income Strategy ETF, uses a synthetic covered-call approach to generate monthly distri...
The AI boom isn’t a one-stock story. Here are three well-positioned names beyond Nvidia that could fuel the next rall...
A deep dive into the IPO prospectus reveals practical lessons every investor should know. Here are more things learne...